# Triple Negative Breast Neoplasms trials: 35 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 35 trials with no drug phase for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Triple Negative Breast Neoplasms trials with no drug phase: 35 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/not-applicable/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 35
- Recruiting or not yet: 35
- Read on: November 19, 2026

## Trials

The 25 newest of 35, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 21, 2026 | NCT07884721 | Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer | FASTEN | Not applicable | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884721) |
| September 29, 2026 | NCT07847398 | Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer. | Centre Antoine Lacassagne | Not applicable | Not yet recruiting | Triple-negative Breast Cancer (TNBC), Stage II-III | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847398) |
| September 28, 2026 | NCT07844473 | Use of Magtrace Bracketing for Excision of Lesion and Sentinel Lymph Node Localization in Breast Conserving Surgery for Breast Cancer | King Faisal Specialist Hospital & Research Center | Not applicable | Recruiting | Breast Cancer With Low to Intermediate HER2 Expression, Breast Cancer (Triple Negative Breast Cancer (TNBC)), Breast... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844473) |
| August 20, 2026 | NCT07776951 | Physical Activity and Healthy Aging: Promoting Cardio-metabolic Capacity to Fight Chronic Inflammation and Improve Outcomes in Breast... | University of Milan | Not applicable | Recruiting | Breast Cancer | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776951) |
| August 3, 2026 | NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | City of Hope Medical Center | Not applicable | Recruiting | Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC... | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741968) |
| June 29, 2026 | NCT07672431 | Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression | Barbara Ann Karmanos Cancer Institute | Not applicable | Not yet recruiting | Triple Negative Breast Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672431) |
| May 19, 2026 | NCT07597642 | ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies... | IRCCS San Raffaele | Not applicable | Not yet recruiting | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07597642) |
| April 29, 2026 | NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | Sponsor not shown (see the record) | Not applicable | Recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer)... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555210) |
| April 13, 2026 | NCT07525869 | An Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC... | Yonsei University | Not applicable | Recruiting | Triple-Negative Breast Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07525869) |
| April 7, 2026 | NCT07513311 | A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer | Massachusetts General Hospital | Not applicable | Recruiting | Triple Negative Breast Cancer (TNBC) | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513311) |
| March 17, 2026 | NCT07478705 | Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging | Sunnybrook Health Sciences Centre | Not applicable | Not yet recruiting | Triple Negative Breast Cancer, Surveillance, Recurrence, ctDNA | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478705) |
| January 22, 2026 | NCT07357948 | Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy | Institut Curie | Not applicable | Not yet recruiting | Triple Negative Breast Cancer, Non-Metastatic | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07357948) |
| December 2, 2025 | NCT07258563 | The TASTY-steering Study | University Medical Center Groningen | Not applicable | Recruiting | Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer, Stage II-IV Diffuse Large B Cell Lymphoma | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07258563) |
| September 23, 2025 | NCT07187674 | The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined... | Harbin Medical University | Not applicable | Not yet recruiting | Triple Negative Breast Cancer (TNBC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07187674) |
| July 16, 2025 | NCT07067138 | A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) | National Cancer Institute (NCI) | Not applicable | Recruiting | Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07067138) |
| July 15, 2025 | NCT07066189 | Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC | Yale University | Not applicable | Recruiting | Triple Negative Breast Cancer | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07066189) |
| July 1, 2025 | NCT07046455 | Trop-2 Targeted PET Probes in Advanced TNBC | Peking University Cancer Hospital & Institute | Not applicable | Recruiting | TNBC - Triple-Negative Breast Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07046455) |
| May 16, 2025 | NCT06975644 | Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) | Zhejiang Provincial People's Hospital | Not applicable | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06975644) |
| May 8, 2025 | NCT06962163 | Assessement of Potential Interest of \[68Ga\]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients | Institut Cancerologie de l'Ouest | Not applicable | Recruiting | Metastatic Breast Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06962163) |
| March 17, 2025 | NCT06879704 | Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer | Centre Henri Becquerel | Not applicable | Recruiting | Triple Negative Breast Cancer | 115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06879704) |
| September 3, 2024 | NCT06582615 | Food for Thought - A Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer | Ohio State University Comprehensive Cancer Center | Not applicable | Recruiting | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06582615) |
| July 11, 2024 | NCT06497322 | Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment | University Hospital of Cologne | Not applicable | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06497322) |
| May 21, 2024 | NCT06422455 | Access to Genetic Testing in Underserved Patients With Cancer | University of Southern California | Not applicable | Recruiting | Breast Carcinoma, Male Breast Carcinoma, Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Ovarian Carcinoma... | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06422455) |
| April 17, 2024 | NCT06371274 | A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. | First Affiliated Hospital of Zhejiang University | Not applicable | Recruiting | Triple-negative Breast Cancer | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06371274) |
| April 5, 2024 | NCT06349512 | 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer (FAP-IT) | Institut Curie | Not applicable | Recruiting | Triple Negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06349512) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Institut Curie | 4 |
| Ohio State University Comprehensive Cancer Center | 2 |
| European Institute of Oncology | 2 |
| FASTEN | 1 |
| Massachusetts General Hospital | 1 |
| Zhejiang Provincial People's Hospital | 1 |
| Institut Cancerologie de l'Ouest | 1 |
| University of Milan | 1 |
| Sunnybrook Health Sciences Centre | 1 |
| IRCCS San Raffaele | 1 |
| Harbin Medical University | 1 |
| Yonsei University | 1 |
| M.D. Anderson Cancer Center | 1 |
| University Medical Center Groningen | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| City of Hope Medical Center | 1 |
| King Faisal Specialist Hospital & Research Center | 1 |
| The Netherlands Cancer Institute | 1 |
| National Cancer Institute (NCI) | 1 |
| Vastra Gotaland Region | 1 |
| Peking University Cancer Hospital & Institute | 1 |
| Thomas Jefferson University | 1 |
| University of Southern California | 1 |
| Yale University | 1 |
| Barbara Ann Karmanos Cancer Institute | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 11 |
| France | 8 |
| Italy | 4 |
| South Korea | 2 |
| China | 2 |
| Netherlands | 1 |
| Saudi Arabia | 1 |
| Sweden | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Window suppliers in the United States](https://specstream.ai/data/businesses/window-suppliers/united-states)
- [Ski resorts in the United States](https://specstream.ai/data/businesses/ski-resorts/united-states)
- [Paralegal companies in the United States](https://specstream.ai/data/businesses/paralegal-companies/united-states)
- [Irrigation contractors in the United States](https://specstream.ai/data/businesses/irrigation-contractors/united-states)
- [Fast food restaurants in the United States](https://specstream.ai/data/businesses/fast-food-restaurants/united-states)
- [Cleaning companies in the United States](https://specstream.ai/data/businesses/cleaning-companies/united-states)
